LANXESS Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

LANXESS Aktiengesellschaft
LANXESS Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
25.01.2024 / 17:37 CET/CEST
Dissemination of a Voting Rights Announcement transmitted by EQS News – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Notification of Major Holdings

1. Details of issuer

Name:LANXESS Aktiengesellschaft
Street:Kennedyplatz 1
Postal code:50569
City:Cologne
Germany
Legal Entity Identifier (LEI):529900PTLRE72EMYIJ77

>
2. Reason for notification

XAcquisition/disposal of shares with voting rights
Acquisition/disposal of instruments
Change of breakdown of voting rights
Other reason:

>
3. Details of person subject to the notification obligation

Legal entity: Ministry of Finance on behalf of the State of Norway
City of registered office, country: Oslo, Norway

>
4. Names of shareholder(s)
holding directly 3% or more voting rights, if different from 3.

Norges Bank

>
5. Date on which threshold was crossed or reached:

24 Jan 2024

>
6. Total positions

% of voting rights attached to shares
(total of 7.a.)
% of voting rights through instruments
(total of 7.b.1 + 7.b.2)
Total of both in %
(7.a. + 7.b.)
Total number of voting rights pursuant to Sec. 41 WpHG
New3.07 %0.20 %3.28 %86346303
Previous notification2.08 %1.27 %3.36 %/

>
7. Details on total positions
a. Voting rights attached to shares (Sec. 33, 34 WpHG)

ISINAbsoluteIn %
Direct
(Sec. 33 WpHG)
Indirect
(Sec. 34 WpHG)
Direct
(Sec. 33 WpHG)
Indirect
(Sec. 34 WpHG)
DE0005470405026524000.00 %3.07 %
Total26524003.07 %

>
b.1. Instruments according to Sec. 38 (1) no. 1 WpHG

Type of instrumentExpiration or maturity dateExercise or conversion periodVoting rights absoluteVoting rights in %
Shares on loan (right to recall)N/AAt any time1762930.20 %
Total1762930.20 %

>
b.2. Instruments according to Sec. 38 (1) no. 2 WpHG

Type of instrumentExpiration or maturity dateExercise or conversion periodCash or physical settlementVoting rights absoluteVoting rights in %
00.00 %
Total00.00 %

>
8. Information in relation to the person subject to the notification obligation

Person subject to the notification obligation is not controlled nor does it control any other undertaking(s) that directly or indirectly hold(s) an interest in the (underlying) issuer (1.).
XFull chain of controlled undertakings starting with the ultimate controlling natural person or legal entity:

>

Name% of voting rights (if at least 3% or more)% of voting rights through instruments (if at least 5% or more)Total of both (if at least 5% or more)
State of Norway % % %
Norges Bank3.07 % % %

>
9. In case of proxy voting according to Sec. 34 para. 3 WpHG
(only in case of attribution of voting rights in accordance with Sec. 34 para. 1 sent. 1 No. 6 WpHG)

Date of general meeting:
Holding total positions after general meeting (6.) after annual general meeting:

Proportion of voting rightsProportion of instrumentsTotal of both
% % %

>
10. Other explanatory remarks:

>
Date

25 Jan 2024

>

25.01.2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com



Veröffentlicht am 25.01.2024

Aktuelle Research Artikel

Biotechnologie

Warum diese Biotech-Aktie in Ihr Depot gehört

Defence Therapeutics Inc. Aktie (WKN: A3CN14): Defence Therapeutics, ein Biotech-Unternehmen aus Kanada, bietet mit seiner Accum®-Technologie eine innovative Plattform zur effektiveren Behandlung von Krebs und Infektionskrankheiten.
Rohstoffe

Graphen verändert die Welt und die Argo Graphene Aktie ist ganz vorne dabei

Argo Graphene Solutions Corp. Aktie (WKN: A41C57): Argo Aktie steht für ein Unternehmen, das mit Graphen, einem starken, dünnen und leitfähigen Material, Branchen revolutionieren könnte.
Biotechnologie

BioNxt: Neue Ära der Chemotherapie und in der ODF-Pipeline mit Kursziel 2,50 EUR

BioNxt Solutions Inc. Aktie (WKN: A3D1K3): BioNxt Solutions entwickelt gezielte Krebstherapien und sublinguale Schmelzfilme, um Nebenwirkungen zu reduzieren und Patientenkomfort zu erhöhen.
Rohstoffe

Kursziel 8,55 EUR: Warum Analysten in Rektron großes Potenzial sehen

Rektron Group Inc. Aktie (WKN: A407W8): Rektron Group Inc. ist ein agiler Rohstoffhändler, der sich auf Nachhaltigkeit und digitale Trends konzentriert und in Wachstumsmärkten wie Indien, Vietnam und Afrika expandiert.
 Ja, ich möchte den Newsletter abonnieren!*
* Sie können sich jederzeit aus dem Newsletter heraus abmelden. Weitere Informationen zum Thema Datenschutz erhalten Sie in unserer Datenschutzerklärung